Newsletter March 2022

Register now for our next IRD Invest virtual investor conference, where emerging tech companies will talk about the tailwinds driving their businesses

March 25th, 2022 by Michael Lovesey

CEO in focus - Pureprofile's Martin Filz

March 24th, 2022 by Paul Langley

UniSeed: UniSuper makes first venture capital foray with $75m funding (afr.com)

March 24th, 2022 by Jane Lowe

Servatus launches new trial into the effects of live biotherapeutics on insomnia

Servatus launches new trial into the effects of live biotherapeutics on insomnia, we talk to CEO Dr Wayne Finlayson to discuss this exciting initiative.

March 24th, 2022 by Michael Lovesey

Kazia begins phase II study into paxalisib + a keto diet to treat brain cancer

Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)

March 23rd, 2022 by Cherie Hartley

Recent client coverage highlights

March 23rd, 2022 by Paul Langley

Project: 2025

Join us on Thurs 31 March for "IRD Invest - Project 2025"

As we look to accelerate the integration of advanced technology over the next three years, our fourth IRD Invest conference considers some of the benefits this change will bring, for businesses and society.

We are delighted to showcase a select number of emerging ASX listed tech companies on 31 March. The free virtual event will focus on companies that are paving the way forward with major advances in technology and innovation.

March 21st, 2022 by Admin